Cancer Cells Respond to Diabetes, Hypertension Drug Combination

Article

Drug combination more effective on cancer cell proliferation.

A combination of drugs used to treat diabetes and hypertension may effectively combat cancer.

Although the type 2 diabetes drug metformin has demonstrated anti-cancer properties, the usual therapeutic dose is too low to treat cancer.

In a study published in Science Advances, investigators found that the antihypertensive drug syrosingopine potentiates the anti-cancer efficacy of metformin. Meaning, the drug combination drives cancer cells to programmed suicide.

Higher doses of metformin can inhibit the growth of cancer cells, but can also induce unwanted adverse events. For the study, the investigators screened more than 1000 drugs to determine whether they could enhance the anti-cancer action of metformin, before selecting syrosingopine.

“For example, in samples from leukemia patients, we demonstrated that almost all tumor cells were killed by this cocktail and at doses that are actually not toxic to normal cells,” said first study author Don Benjamin. “And the effect was exclusively confined to cancer cells, as the blood cells from health donors were insensitive to the treatment.”

The investigators conducted an experiment in mice with malignant liver cancer who were administered the combination therapy. The results of the study showed that enlargement of the liver was reduced, and the number of tumor nodules either lowered or completely disappeared.

Metformin, which reduces blood glucose levels, can block the respiratory chain in mitochondria, and syrosingopine inhibits the degradation of glucose. When the drug combination is used, it interrupts the viral processes that provides the cell with energy. Since cancer cells have a high energy consumption, it makes them extremely vulnerable when the energy supply is reduced, according to the study.

The investigators tested a variety of other compounds with the same mode of action to demonstrate that the inhibition of the respiratory chain in the mitochondria is a key mechanism.

“We have been able to show that the 2 known drugs lead to more profound effects on cancer cell proliferation than each drug along,” Benjamin said. “The data from this study support the development of combination approaches for the treatment of cancer patients.”

Related Videos
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
pharmacy | Image Credit: Diego Cervo - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.